ATOZET

This brand name is authorized in Australia, Austria, Ecuador, Germany, Hong Kong SAR China, Ireland, Israel, Japan, Malta, Mexico, Netherlands, Poland, Romania, Singapore, Spain.

Active ingredients

The drug ATOZET contains a combination of these active pharmaceutical ingredients (APIs):

1	Atorvastatin UNII 48A5M73Z4Q - ATORVASTATIN CALCIUM TRIHYDRATE
	Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
	Read more about Atorvastatin
2	Ezetimibe UNII EOR26LQQ24 - EZETIMIBE
	Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol.
	Read more about Ezetimibe

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ATOZET Film-coated tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10BA05		C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BA Combinations of various lipid modifying agents
Discover more medicines within C10BA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10376D, 10377E, 10392Y, 10393B
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	10538255, 10538261, 10538315, 10538321, 10538396, 10538410, 10538491, 10538516, 12478155, 12478161, 12494065, 12494094, 12494148, 12494154, 12494160, 12494177, 12520360, 12520377, 12520383, 12536272, 12536289, 12536295, 12536303, 12733541, 12733558, 12733564, 12733570, 13154621, 13154644, 13154667, 13154696, 13899700, 14055128, 14270140, 14270157, 14270163, 14270186, 14348735, 14404652, 14437723, 14437746, 14437752, 15257868, 15266560, 15266577, 15408155, 15408161, 15424220, 15530293, 15571518, 15571524, 15571530, 16036595, 16227786, 16506405, 16506434, 16606271, 16606288, 16606294, 16606325, 16665210, 16686169
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1964-MEE-0316, 2062-MEE-0516
ES	Centro de información online de medicamentos de la AEMPS	3400928005557, 3400928005786, 34009288005557IP, 79224, 79226, 79227
HK	Department of Health Drug Office	64636, 64637
IE	Health Products Regulatory Authority	36858, 36859, 36862, 36863
IL	מִשְׂרַד הַבְּרִיאוּת	7899, 7900, 7901, 7902
JP	医薬品医療機器総合機構	2189101F1020, 2189101F2026
MT	Medicines Authority	MA031/02401, MA031/02402, MA031/02403, MA031/02404
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	022M2017
NL	Z-Index G-Standaard, PRK	122793, 122807, 122815
PL	Rejestru Produktów Leczniczych	100346646, 100346669, 100346681, 100346706
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68310001, W68310002, W68310003, W68310004, W68310005, W68310006, W68311001, W68311002, W68311003, W68311004, W68311005, W68311006, W68312001, W68312002, W68312003, W68312004, W68312005, W68312006, W68313001, W68313002, W68313003, W68313004, W68313005, W68313006
SG	Health Sciences Authority	15113P, 15114P, 15115P, 15116P